Performance evaluation of a laboratory developed PCR test for quantitation of HIV-2 viral RNA

Management of Human Immunodeficiency Virus Type 2 (HIV-2) infections present unique challenges due to low viral titers, slow disease progression, and poor response to standard antiviral therapies. The need for a nucleic acid assay to detect and quantify HIV-2 virus has led to the development of a number of molecular-based assays for detection and/or quantification of HIV-2 viral RNA in plasma in order to provide laboratory evidence of HIV-2 infection and viral loads for use in treatment decisions. As HIV-2 is less pathogenic and transmissible than HIV-1 and has resistance to several of the antiretroviral drugs, delay of treatment is common. Cross sero-reactivity between HIV-1 and HIV-2 makes it difficult to distinguish between the two viruses based upon serological tests. As such we developed a quantitative reverse transcription PCR (qRT-PCR) assay targeting the 5’ long terminal repeat of HIV-2 for detection and quantification of HIV-2 viral RNA in plasma to identify HIV-2 infection and for use in viral load monitoring. Serial dilutions of cultured HIV-2 virus demonstrated a wide dynamic range (10 to 100,000 copies/ml) with excellent reproducibility (standard deviation from 0.12–0.19), linearity (R2 = 0.9994), and a lower limit of detection at 79 copies/ml (NIH-Z). The assay is highly specific for HIV-2 Groups A and B and exhibits no cross reactivity to HIV-1, HBV or HCV. Precision of the assay was demonstrated for the High (Mean = 6.41; SD = 0.12) and Medium (Mean = 4.46; SD = 0.13) HIV-2 positive controls. Replicate testing of clinical specimens showed good reproducibility above 1,000 copies/ml, with higher variability under 1,000 copies/ml. Analysis of 220 plasma samples from HIV-2 infected West African individuals demonstrated significantly lower viral loads than those observed in HIV-1 infections, consistent with results of previous studies. Slightly more than seven percent of clinical samples (7.3%) demonstrated viral loads above 100,000 copies/ml, while 37.3% of samples were undetectable. The high sensitivity, specificity, precision, and linearity of the WRAIR qRT-PCR assay makes it well suited for detection and monitoring of HIV-2 RNA levels in plasma of infected individuals.

[1]  R. Gangakhedkar,et al.  Partial pol Sequences from Drug Naive HIV-2 Infected Individuals from Maharashtra, India. , 2019, AIDS research and human retroviruses.

[2]  S. Rowland-Jones,et al.  Delayed disease progression in HIV‐2: the importance of TRIM5α and the retroviral capsid , 2019, Clinical and experimental immunology.

[3]  J. Ananworanich,et al.  Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test , 2019, Journal of Clinical Microbiology.

[4]  R. Serrão,et al.  Human Immunodeficiency Virus (HIV) 2 Superinfection in a Patient Receiving Antiretroviral Therapy With Longstanding HIV-1 Viral Load Suppression , 2019, Open forum infectious diseases.

[5]  L. Styer,et al.  Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana , 2019, Medicine.

[6]  G. Gottlieb,et al.  90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. , 2018, The lancet. HIV.

[7]  C. Wejse,et al.  The influence of human leukocyte antigen-types on disease progression among HIV-2 infected patients in Guinea-Bissau , 2018, AIDS.

[8]  J. Mendieta,et al.  Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway , 2017, The Journal of Biological Chemistry.

[9]  G. Gottlieb,et al.  Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  Shaowu Tang,et al.  Correct Use of Percent Coefficient of Variation (%CV) Formula for Log-Transformed Data , 2017 .

[11]  C. Morrison,et al.  CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study , 2017, The Journal of antimicrobial chemotherapy.

[12]  C. Rouzioux,et al.  New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification , 2017, Journal of Clinical Microbiology.

[13]  V. Soriano,et al.  Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response , 2017, The Journal of antimicrobial chemotherapy.

[14]  V. Soriano,et al.  HIV type 2 epidemic in Spain: challenges and missing opportunities , 2017, AIDS.

[15]  C. Nkoke,et al.  UNAIDS 90–90–90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades” , 2017, BMJ Global Health.

[16]  C. Charpentier,et al.  Hiv-2 molecular epidemiology. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[17]  C. Wejse,et al.  High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau - a cohort study from West Africa , 2016, The Pan African medical journal.

[18]  F. Dabis,et al.  Mortality and survival patterns of people living with HIV-2 , 2016, Current opinion in HIV and AIDS.

[19]  S. Rowland-Jones,et al.  Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2–Infected Controllers , 2016, The Journal of Immunology.

[20]  Guixia Yu,et al.  Two human immunodeficiency virus Type 2 cases in US blood donors including serologic, molecular, and genomic characterization of an epidemiologically unusual case , 2016, Transfusion.

[21]  N. Hasegawa,et al.  Qualitative Real-Time PCR Assay for HIV-1 and HIV-2 RNA. , 2016, Japanese journal of infectious diseases.

[22]  J. Sterne,et al.  Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort , 2016, Journal of the International AIDS Society.

[23]  C. Charpentier,et al.  Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Charpentier,et al.  Genotypic resistance profiles of HIV-2-treated patients in West Africa , 2014, AIDS.

[25]  V. Jansen,et al.  Protection Versus Pathology in Aviremic and High Viral Load HIV-2 Infection—The Pivotal Role of Immune Activation and T-cell Kinetics , 2014, The Journal of infectious diseases.

[26]  Y. Liu,et al.  Discrepant Amplification Results during the Development of an Assay Leads to Reclassification of Two AIDS Reagent Repository HIV-2 Isolates as HIV-1 , 2014, PloS one.

[27]  P. Goubau,et al.  Validation of an ultrasensitive digital droplet PCR assay for HIV-2 plasma RNA quantification , 2014, Journal of the International AIDS Society.

[28]  M. Parker,et al.  Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[29]  G. Gottlieb,et al.  Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line Therapy , 2013, Antimicrobial Agents and Chemotherapy.

[30]  G. Gottlieb,et al.  Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  F. Månsson,et al.  Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. , 2012, The New England journal of medicine.

[32]  A. Heath,et al.  Preparation and evaluation of the 1st international standard for the quantitation of HIV-2 RNA in plasma. , 2011, Journal of virological methods.

[33]  R. Charrel,et al.  RNA and DNA Bacteriophages as Molecular Diagnosis Controls in Clinical Virology: A Comprehensive Study of More than 45,000 Routine PCR Tests , 2011, PloS one.

[34]  Eileen M. Burd,et al.  Validation of Laboratory-Developed Molecular Assays for Infectious Diseases , 2010, Clinical Microbiology Reviews.

[35]  E. Sanders-Buell,et al.  Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.

[36]  S. Popper,et al.  Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. , 1999, The Journal of infectious diseases.

[37]  J. Mascola,et al.  Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes , 1999, Journal of Clinical Microbiology.

[38]  G. Gottlieb,et al.  Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[39]  HIV-2 Infection Surveillance--United States, 1987-2009. , 2011, MMWR. Morbidity and mortality weekly report.